The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | C | Cardiovascular system | |
2 | C02 | Antihypertensives | |
3 | C02C | Antiadrenergic agents, peripherally acting | |
4 | C02CA | Alpha-adrenoreceptor antagonists |
Code | Title | |
---|---|---|
C02CA01 | Prazosin | |
C02CA02 | Indoramin | |
C02CA03 | Trimazosin | |
C02CA04 | Doxazosin | |
C02CA06 | Urapidil |
Active Ingredient | Description | |
---|---|---|
Doxazosin |
Doxazosin is a potent and selective post-junctional alpha-1-adrenoceptor antagonist. This action results in a decrease in systemic blood pressure. |
|
Indoramin |
Indoramin is an alpha adrenoceptor blocking agent. It acts selectively and competitively on post-synaptic alpha-1 receptors, causing a decrease in peripheral resistance. It also produces relaxation of hyperplastic muscle in the prostate. |
|
Prazosin |
Prazosin causes a decrease in total peripheral vascular resistance through selective inhibition of postsynaptic alpha-1-adrenoreceptors in vascular smooth muscle. Prazosin has been found to successfully reduce the severity of the signs, symptoms, frequency and duration of attacks, in patients with Raynaud’s disease. |
|
Urapidil |
Urapidil is a α1-adrenoceptor antagonist and 5-HT1A receptor agonist and consequently inhibits the vasoconstrictor effect of catecholamines. It interacts with peripheral α1-adrenoceptors and central 5-HT1A receptors to produce vasodilation without sympathetic activation. |
Title | Information Source | Document Type | |
---|---|---|---|
ATODEL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
CARDURA Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
CARDURA XL Extended-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
DORALESE Film-coated tablets | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
HYPOVASE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
KAMIREN Prolonged-release tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
MAGUROL Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
MINIPRESS Capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
RAPORSIN XL Prolonged-release tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
URODOXA Tablet | Health Products Regulatory Authority (ZA) | MPI, Generic |